Cargando…
Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib
In recent years, there has been increasing pressure on public health systems in high-income countries due to high medicines prices, one of the underlying causes of which are the market monopolies granted to pharmaceutical undertakings. These monopolies have been facilitated by expanded forms of inte...
Autores principales: | Hu, Yuanqiong, Eynikel, Dimitri, Boulet, Pascale, Krikorian, Gaelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958714/ https://www.ncbi.nlm.nih.gov/pubmed/31956420 http://dx.doi.org/10.1186/s40545-019-0198-6 |
Ejemplares similares
-
We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis
por: Krikorian, Gaëlle, et al.
Publicado: (2021) -
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015) -
Access to innovative oncology medicines in Europe
por: Bergmann, L., et al.
Publicado: (2016) -
Examination for Certificate in Psychological Medicine
Publicado: (1886) -
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)